Global Recombinant Therapeutic Antibodies and Proteins Market Growth (Status and Outlook) 2025-2031

According to this study, the global Recombinant Therapeutic Antibodies and Proteins market size will reach US$ million by 2031.

Therapeutic proteins are engineered in the laboratory for pharmaceutical use, including non-covalent binders. These proteins are highly effective and serve as modernized treatment for rare as well as chronic diseases. Protein therapeutics offer custom-made treatment approach by supporting a specifically targeted therapeutic process by compensating the deficiency of an essential protein. Recombinant proteins have gained significant traction for therapeutic applications and the number of proteins either launched or approved into clinical trials has continually increased over the past two decades. According to the National Center for Biotechnology Information (NCBI) data of 2017, the U.S. Food and Drug Administration (FDA) approved over 140 recombinant therapeutic proteins for human use and several hundred are currently in development. Majority of these proteins are recombinant monoclonal antibodies.

The global recombinant therapeutic antibodies and proteins market size was valued at US$ 92.5 billion in 2017, and is expected to witness a robust CAGR of 11.2% over the forecast period (2017 – 2025).

LPI (LP Information)' newest research report, the “Recombinant Therapeutic Antibodies and Proteins Industry Forecast” looks at past sales and reviews total world Recombinant Therapeutic Antibodies and Proteins sales in 2024, providing a comprehensive analysis by region and market sector of projected Recombinant Therapeutic Antibodies and Proteins sales for 2025 through 2031. With Recombinant Therapeutic Antibodies and Proteins sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Therapeutic Antibodies and Proteins industry.

This Insight Report provides a comprehensive analysis of the global Recombinant Therapeutic Antibodies and Proteins landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Recombinant Therapeutic Antibodies and Proteins portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Recombinant Therapeutic Antibodies and Proteins market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Therapeutic Antibodies and Proteins and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Therapeutic Antibodies and Proteins.

This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Therapeutic Antibodies and Proteins market by product type, application, key players and key regions and countries.

Segmentation by Type:
Plasma Protein
Fusion Proteins
Monoclonal Antibodies
Hormones
Enzyme
Coagulation Factors
Others

Segmentation by Application:
Oncology
Hematology
Immunology
Endocrinology
Infectious Disease
Cardiovascular Disease
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abbott
Amgen
Biogen
Eli Lilly
Roche
Johnson and Johnson
Merck
Novo Nordisk
Pfizer
Sanofi

Please note: The report will take approximately 2 business days to prepare and deliver. Show more